Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

TOPIGEN Appoints Biopharmaceutical Industry Executives

By Pharmaceutical Processing | March 30, 2005

TOPIGEN Pharmaceuticals Inc., a developer of anti-inflammatory respiratory products that inhibit multiple pathways, today announced that its board of directors has appointed two experienced executives, effective immediately. Joining the board are Gary Lessing and Michael Atkin, both as directors. “With the appointments of Gary and Mike, our board is now complete,” said Dr Paul K. Wotton, Ph.D, TOPIGEN’s President and Chief Executive Officer. “Our two new board members bring a wealth of experience in financing and licensing. We look forward to their guidance as we pursue our corporate strategy” Gary Lessing.

Mr. Lessing is Chief Financial Officer at Avalon Pharmaceuticals, a privately-held, Maryland-based corporation. Avalon is engaged in discovering and developing innovative small-molecule therapeutics using its comprehensive genomics approach. At Avalon, Mr. Lessing is responsible for a wide range of strategic and financial management activities.

Prior to joining Avalon, he was Managing Director of the healthcare investment banking group at Deutsche Banc Alex Brown (DBAB). While at DBAB, Mr. Lessing focused on providing investment banking services, including mergers and acquisitions, strategic advisory assignments and public financings for healthcare and life sciences clients. He also served as head of the firm’s European healthcare investment banking group.

“TOPIGEN’s recent $20 million venture financing provides a solid foundation for future capital support and advancement of the Company’s pipeline,” said Mr. Lessing. “I am pleased to be able to work with TOPIGEN’s management and its investors in driving the company forward.”

Mr. Atkin is President and Chief Executive Officer of Aegera Therapeutics, a privately-held, Quebec-based company focused on extending and enhancing the lives of cancer patients. He has extensive business development experience in both the US and Canada, including managing numerous licensing, collaborative and financing initiatives. Among his many accomplishments, Mr. Atkin successfully led the merger of Exogen Neurosciences with Apoptogen, founding Aegera.

“TOPIGEN is uniquely positioned to impact the respiratory-disease market as it moves new drug candidates, with first in class mechanisms, from discovery to clinical development,” said Mr. Atkin. “I am excited to be a part of its future.”

Prior to Aegera, Mr. Atkin was President and Chief executive Officer of Exogen Neurosciences. Prior to moving to Canada, he was Director, New Products at Bristol-Myers Squibb in Princeton, NJ where he created and implemented global branding and product development strategies. Previously he was Vice President of Business Development at Lederle International where he led licensing and acquisition initiatives.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE